REFERENCES
- Gragoudas E S, Adamis A P, Cunningham E T, Jr., Feinsod M, Guyer D R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27)2805–2816
- Kaiser P K. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142(4)660–668
- Rosenfeld P J, Brown D M, Heier J S, Boyer D S, Kaiser P K, Chung C Y, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14)1419–1431
- Grazul-Bilska A T, Johnson M L, Bilski J J, Redmer D A, Reynolds L P, Abdullah A, et al. Wound healing: the role of growth factors. Drugs Today (Barc) 2003; 39(10)787–800
- Chou E, Suzuma I, Way K J, Opland D, Clermont A C, Naruse K, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105(3)373–379
- US Food and Drug Administration. MedWatch. Barron, Genentech H. Important drug warning (letter), http://www.fda.gow/medwatch/Safety/2005/Avastin_dearhcp.pdf 2005 [cited]
- Tezel T H, Barr C C, Kaplan H J. Intravitreally injected anti-VEGF drugs exert a biological effect in the fellow eye. 24th Annual Meeting of the American Society of Retina Specialists, CannesFrance, 2006